Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 5,000 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 5,000 shares of Akero Therapeutics stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $20.15, for a total value of $100,750.00. Following the sale, the chief operating officer now directly owns 258,306 shares of the company’s stock, valued at $5,204,865.90. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jonathan Young also recently made the following trade(s):

• On Monday, April 1st, Jonathan Young sold 5,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $24.38, for a total value of $121,900.00.

Akero Therapeutics Price Performance

Shares of NASDAQ:AKRO opened at $19.66 on Friday. Akero Therapeutics, Inc. has a one year low of $11.25 and a one year high of $58.38. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -6.90 and a beta of -0.29. The company has a 50-day simple moving average of $24.43 and a 200-day simple moving average of $20.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 29.27 and a current ratio of 29.27.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.17). On average, analysts predict that Akero Therapeutics, Inc. will post -3.93 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on AKRO shares. HC Wainwright increased their price target on shares of Akero Therapeutics from $40.00 to $43.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Bank of America assumed coverage on shares of Akero Therapeutics in a report on Monday, April 22nd. They issued a “neutral” rating and a $30.00 target price for the company. Finally, UBS Group lifted their target price on Akero Therapeutics from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Akero Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $37.71.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Headlands Technologies LLC acquired a new stake in shares of Akero Therapeutics during the fourth quarter worth $28,000. Quarry LP lifted its stake in shares of Akero Therapeutics by 40.0% in the 4th quarter. Quarry LP now owns 1,750 shares of the company’s stock worth $41,000 after acquiring an additional 500 shares during the period. Strs Ohio lifted its stake in shares of Akero Therapeutics by 100.0% in the 4th quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $46,000 after acquiring an additional 1,000 shares during the period. Orion Capital Management LLC purchased a new stake in shares of Akero Therapeutics in the third quarter valued at about $51,000. Finally, Quest Partners LLC acquired a new position in shares of Akero Therapeutics during the fourth quarter worth about $75,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.